Paclitaxel (PTX) has proven an effective anti-canceragent when delivered intravenously as oil or albuminbased formulations. Here we described the preparation ofpaclitaxel : polyethyleneglycol-b-poly(methacrylic acidco-n-butylmethacrylate) (PTX:PEG-PMA) diblockcopolymer micelles for oral administration and provide invitro and in vivo data which shows them to effectivelypromote PTX translocation across Caco II monolayersand achieve well tolerated, significant oral bioavialabilityof PTX in a rodent model. Such data suggest PEG-PMAmay prove an effective oral formulation of PTX whichmerit clinical study.
展开▼
